Trial Profile

Collection of Long-Term Outcome Data for Subjects Who Have Previously Participated in Selected Ipilimumab (MDX-010) Studies in Metastatic Melanoma.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Dacarbazine
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors Medarex

Most Recent Events

16 Jan 2010 Long-term results for 64 patients enrolled on MDX010-08 have been published online in Investigational New Drugs in conjunction with results of the original protocol.
08 Oct 2009 Actual patient number (160) added as reported by ClinicalTrials.gov.
29 Jun 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com